Abstract
HER2 overexpression/amplification in patients with RAS wild-type (WT) mCRC may be associated with resistance to standard of care anti-EGFR therapies. However, there are no meta-analyses investigating this association. Our objective was to assess the predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
